Identifying viable study sites presents a challenge in many clinical trials. Biosimilar development is especially challenging as the number of sponsors preparing to broaden access to today’s blockbuster biologics, by providing lower-cost biosimilar alternative, continues to grow. While this flood of research activity will make a significant improvement for patient …
![Biosimilars Covance](https://ddblog.labcorp.com/wp-content/uploads/2018/01/Lab-Scene.jpg)